HTL 0016878
Alternative Names: HTL-0016878; NBI-1117568; NBI-568Latest Information Update: 06 Jun 2025
At a glance
- Originator Heptares Therapeutics
- Developer AbbVie; Neurocrine Biosciences; Nxera Pharma
- Class Antidementias; Antipsychotics; Small molecules
- Mechanism of Action Muscarinic M4 receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Phase III Schizophrenia
- No development reported Alzheimer's disease
Most Recent Events
- 28 May 2025 Efficacy and adverse events data from a phase II trial in Schizophrenia released by Neurocrine Biosciences
- 01 May 2025 Phase-III clinical trials in Schizophrenia in USA (PO) (NCT06963034) (9443892_
- 14 Jan 2025 Neurocrine Biosciences plans a phase III trial in Schizophrenia in first half of 2025